J.P. Morgan Healthcare Conference Presentation
Delivering on commitments to growth.
Performance underpins confidence in medium-term targets
2021-2026 outlook
Metric
On track
Growth
Sales
Adj. operating profit
Vaccines
Specialty Medicines
General Medicines
Adj. operating margin
Cash generated from Operations
>5% CAGR
>10% CAGR
High-single-digit % CAGR
Double digit % CAGR
Broadly stable
>30% by 2026
>£10bn by 2026
beyond 2026
driven by
continued
execution
and pipeline
progress
GSK
CAGR: Compound annual growth rate at constant exchange rates (CER)
All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statement in the Q2 2023 earnings release and the 2022 Annual Report.
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. CAGR is for the 5 years to 2026, using 2021 as the
base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above.
4View entire presentation